Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioCryst ( (BCRX) ) has issued an update.
Effective January 9, 2026, BioCryst Pharmaceuticals raised the U.S. wholesale acquisition cost of its hereditary angioedema treatment ORLADEYO (berotralstat) from $44,484.33 to $48,487.92 per 28-day pack, covering both the 150 mg and 110 mg capsule strengths, marking a notable price increase for one of the company’s key rare-disease products and with potential implications for payers and patient access.
The most recent analyst rating on (BCRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
BioCryst’s overall stock score reflects a mix of strong strategic moves and significant financial challenges. The positive impact of recent corporate events and earnings call guidance is offset by weak financial performance and valuation metrics. The company’s ability to address financial risks and capitalize on strategic initiatives will be crucial for future performance.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing oral therapies, including ORLADEYO (berotralstat), for rare diseases in the United States market.
Average Trading Volume: 5,084,399
Technical Sentiment Signal: Sell
Current Market Cap: $1.67B
See more insights into BCRX stock on TipRanks’ Stock Analysis page.